Observations placeholder
Revlimid
Identifier
020143
Type of Spiritual Experience
Number of hallucinations: 261
Background
A description of the experience
Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004. It is used as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). It costs $163,381 per year for the average patient
On Dec, 29, 2016 117,888 people reported to have side effects when taking Revlimid. Among them, 261 people (0.22%) have Hallucination
Time on Revlimid when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 60.00% | 32.73% | 3.64% | 1.82% | 1.82% | 0.00% | 0.00% |
On Jan, 19, 2016: 42,911 people reported to have side effects when taking Revlimid. Among them, 7,390 people (17.22%) have Death.
Time on Revlimid when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 33.48% | 42.12% | 12.42% | 7.66% | 4.32% | 0.00% | 0.00% |
Gender of people who have Death when taking Revlimid :
| Female | Male | |
| Death | 41.81% | 58.19% |
Age of people who have Death when taking Revlimid :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.01% | 0.00% | 0.26% | 0.58% | 3.32% | 11.93% | 83.90% |
Top conditions involved for these people :
- Multiple myeloma (5,908 people, 79.95%)
- Myelodysplastic syndrome (1,118 people, 15.13%)